Immunosuppression regimen modification during COVID-19 infection in kidney transplant recipients
Transplant Immunology · 2023
DOI: 10.1016/j.trim.2023.101883 ↗Kurz gefasst
Fachartikel in der Zeitschrift Transplant Immunology, 2023. Verfasst von Mahmoudreza Moein und 5 weiteren Autor:innen. Beteiligte Einrichtung: Department of Surgery, Division of Transplantation, SUNY Upstate Medical University, Syracuse, NY, USA. Hauptthemen laut MEDLINE: Kidney Transplantation, COVID-19, Immunosuppressive Agents, SARS-CoV-2. Die Arbeit wurde bisher 3-mal zitiert (Crossref) und nennt 20 Literaturangaben.
Abstract (Originalsprache)
BACKGROUND: COVID-19 pandemic had tremendously affected all the aspects of human life during the past 3 years. In this study, we focused on kidney transplant patients' course from the COVID-19 diagnosis, immunosuppressive medication modification, hospitalization, and COVID-19 complications and how the COVID-19 infection affected the kidney and patients' quality of life during the hospitalization and after the discharge. MATERIAL AND METHOD: A retrospective analysis of a prospectively collected database of all kidney transplants adult patients who had a positive COVID-19 PCR from 1 January 2020 to 30 December 2022, and had a history of kidney transplant at the SUNY Upstate Medical Hospital was done to identify the cases. RESULTS: 188 patients met the inclusion criteria and were included in the study. Based on the immunosuppressive regimen modification during COVID-19 infection, patients divided into two groups; in 143 (76%) patients, the immunosuppressive medication was reduced, and in 45 (24%) of patients, the immunosuppressive regimen continued as before during the COVID-19 infection. The mean time from the transplant to the diagnosis of COVID-19 was 67 months in the group we reduced the IM regimen, and 77 months in the group without changes in IM regimen. The mean recipients' age was 50.7 ± 12.9 years in the group we reduced the IM regimen, and 51.8 ± 16.4 years in the group without changes in IM regimen (P = 0.64). The vaccination rate against COVID-19 with at least 2 doses of either the CDC recommended Moderna or Pfizer vaccines was 80.2% in the group we reduced the IM regimen, and 84.8% in the group without changes in IM regimen (P = 0.55). The hospitalization rate due to COVID-19 related symptoms was 22.4% % in the group we reduced the IM regimen, and 35.5% in the group without changes in IM regimen (P = 0.12). However, the ICU admission rate was higher in the group we reduced the IM regimen, but the difference was not significant (26.5% Vs.6.25%, P = 0.12). 6 episodes of biopsy-proven rejection in the group with IM reduction was observed, which were 3 episodes of acute antibody-mediated rejections (ABMR) and 3 episodes of acute T-Cell-mediated rejections (TCMR), and 3 episodes in the group without any change in IM regimen, which were 2 episodes of ABMR and 1 episode of TCMR (P = 0.51). No significant difference was mentioned in the eGFR and serum creatinine after the comparison between the groups after 12 months of follow up. 124 patients responded to the post-COVID-19 questionnaires and were included in the data analysis. The response rate was 66%. Fatigue and exertion were the most reported symptom with a 43.9% prevalence. CONCLUSIONS: We found that immunosuppressive regimen minimization did not impact the kidney function in the long-term and it might be a helpful strategy to minimize the effect of COVID-19 infection on patients' condition during the hospital stay. With all the treatments, vaccinations, and precautions, still some patients did not achieve the complete recovery compared to their pre-COVID-19 health status. Fatigue was the main reported symptom amongst all the reported symptoms.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Surgery, Division of Transplantation, SUNY Upstate Medical University, Syracuse, NY, USA.
- Department of Pathology and Laboratory Medicine, SUNY Upstate Medical University, Syracuse, NY, USA.
- Department of Surgery, Division of Transplantation, SUNY Upstate Medical University, Syracuse, NY, USA. Electronic address: SaidiR@upstate.edu.
Zitieren
APA
Moein, M., Martin, S. J., Whittemore, C., Thankachan, R., Dvorai, R. H., & Saidi, R. F. (2023). Immunosuppression regimen modification during COVID-19 infection in kidney transplant recipients. Transplant Immunology. https://doi.org/10.1016/j.trim.2023.101883
Vancouver
Moein M, Martin SJ, Whittemore C, Thankachan R, Dvorai RH, Saidi RF. Immunosuppression regimen modification during COVID-19 infection in kidney transplant recipients. Transplant Immunology. 2023. doi:10.1016/j.trim.2023.101883
BibTeX
@article{Moein2023,
author = {Moein, Mahmoudreza and Martin, Samuel J and Whittemore, Carter and Thankachan, Reeba and Dvorai, Reut Hod and Saidi, Reza F},
title = {Immunosuppression regimen modification during COVID-19 infection in kidney transplant recipients},
journal = {Transplant Immunology},
year = {2023},
doi = {10.1016/j.trim.2023.101883}
}
EUVIMED